藥石科技(300725.SZ)2021年度淨利潤預增160%-170%
格隆匯1月26日丨藥石科技(300725.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤4.79億元-4.97億元,同比增長160%-170%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤2.26億元-2.43億元,同比增長30%-40%;營業收入11.76億元-12.27億元,同比增長15%-20%。
主營業務影響:(1)2021年,公司貫徹執行“專注化學,搭建高水平的小分子藥物從發現到產業化的技術和服務平台”發展戰略,鞏固分子砌塊業務優勢同時,進一步夯實CDMO業務佈局,完善藥物發現技術服務平台。在產能沒有明顯增長的情況下,通過優化收入結構、改善經營效率、提升產能利用率等措施進一步提升經營規模,預計實現營業收入較2020年度增長15%-20%。公司通過持續的工藝創新、路線優化及規模化生產,有效控制了公司及客户的成本,毛利率較2020年度保持穩定提升。
(2)公司搭建有特色和差異化的CMC服務平台,不斷加強各個業務模塊和技術平台能力建設,在人員儲備、固定資產投入、研發費用投入上有較為明顯的增長。
(3)由於公司向境外銷售產品及提供服務的收入比例較高,收入主要以美元為結算貨幣,2021年度美元兑換人民幣平均匯率相比上年降幅達6.9%,對公司營業收入及淨利潤有一定負面影響。
2021年度預計非經常性損益對淨利潤的影響金額約2.5億-2.6億元,主要因公司2021年4月完成對聯營企業浙江暉石16.5%股權的收購,浙江暉石成為公司控股子公司,購買日之前持有的股權37.43%按照公允價值重新計量產生的利得。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.